A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer
Abstract Background Medullary Thyroid Carcinoma (MTC) is closely associated with mutations in the RET proto-oncogene, placing the activated RET protein at the center of MTC pathogenesis. Existing therapeutic solutions, primarily tyrosine kinase inhibitors such as selpercatinib, vandetanib, and caboz...
Saved in:
| Main Authors: | Tariq Alqahtani, Arwa Alsubait, Meshari Aloumi, Abdulrahman Alamer, Ghala Alomari, Osama I. Alwassil, Ahmad J. Obaidullah, Sahar S. Alghamdi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-13345-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Familial Clinical Heterogeneity of Medullary Thyroid Cancer with Germline RET S891A Protooncogene Mutation: 7-year Follow-up with Successful Sorafenib Treatment
by: Sirmen Kızılcan Çetin, et al.
Published: (2025-09-01) -
Next-Generation Sequencing Reveals the Potential Role of RET Protooncogene in Metastasis Progression in Medullary Thyroid Cancer
by: Maurice Klein, et al.
Published: (2025-07-01) -
Overview of management and therapeutic advances in medullary thyroid cancer
by: Mark A Jara, et al.
Published: (2025-03-01) -
Acute severe hypocalcaemia after initiation of a selective RET-inhibitor in medullary thyroid cancer
by: Leslie Cheng, et al.
Published: (2025-02-01) -
Surgical and clinical strategies in the management of thyroid medullary carcinoma in children with and without ret proto-oncogene mutations
by: Özlem Boybeyi-Türer, et al.
Published: (2016-08-01)